Startup Signos leverages AI and CGMs to provide affordable, accessible tools for everyday Americans battling weight challenges
The FDA’s approval of Signos’ AI-powered glucose monitoring system for weight loss marks a pivotal moment in obesity management. Unlike restrictive treatments such as costly GLP-1 drugs or surgery, Signos democratizes access to personalized, data-driven weight management tools through wearable CGMs. At $129–$139 per plan, it offers affordability relative to existing therapies, though insurance coverage remains a hurdle. With obesity-related healthcare costs exceeding $170 billion annually and nearly three-quarters of Americans overweight, this innovation could have transformational public health impact. Beyond weight loss, Signos emphasizes behavioral insights—empowering users to understand their bodies and sustain healthier lifestyles long-term.
The Meals and Drug Administration on Wednesday authorised the first-ever glucose monitoring system particularly for weight reduction from the startup Signos, establishing a brand new choice for Individuals to handle their weight.
Present therapy choices for shedding weight – fashionable medication like GLP-1s and surgical interventions – are usually restricted to sufferers with weight problems or a sure BMI. Weight problems medication reminiscent of Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound may also be tough to entry on account of their excessive prices, restricted U.S. insurance coverage protection and constrained provide.
However now, any affected person can buy a Signos membership to entry its system. It makes use of an AI platform and an off-the-shelf steady glucose monitor, or CGM, from Dexcom to supply customized, real-time knowledge and way of life suggestions for weight administration.
“There may be now an answer that everyone can use to assist on the burden loss journey, and you do not have to be a sure variety of kilos to make use of it. It is accessible for the common American who wants it,” mentioned Sharam Fouladgar-Mercer, Signos’ co-founder and CEO, in an interview on Tuesday forward of the approval. “The typical individual might need 5 kilos to lose, or others might need 100 kilos to lose. We’re right here to assist them at any level in that journey.”
The weight problems epidemic prices the U.S. health-care system greater than $170 billion a yr, in response to Facilities for Illness Management and Prevention knowledge. Virtually 74% of Individuals are chubby or overweight, authorities knowledge says. Signos hopes it will possibly make a “actual massive dent in that curve for the betterment of many people,” Fouladgar-Mercer mentioned.
Clients who join Signos can select a three-month or six-month plan, which at the moment prices $139 and $129, respectively. The corporate will ship out all the CGMs a affected person wants for the variety of months within the plan they select.
Insurers at the moment do not cowl the system for weight administration, however the plans are a fraction of the roughly $1,000 month-to-month value of GLP-1s within the U.S. Signos is working with medical health insurance firms and employers to get protection for the system, the corporate mentioned in a press release to CNBC. Signos mentioned it expects “this to evolve rapidly as curiosity for tackling weight continued to broaden.”
The Signos system can be utilized together with GLP-1s or bariatric surgical procedure, mentioned Fouladgar-Mercer. He mentioned sufferers can even use the system after getting off a GLP-1 to take care of their weight reduction.
CGMs are small sensors worn on the higher arm that observe glucose ranges, primarily for individuals with diabetes. That knowledge is wirelessly despatched to Signos’ app, which additionally permits sufferers to log their meals consumption and train ranges, amongst different info that the AI platform makes use of to make suggestions.
Other than serving to individuals lose kilos, the system goals to assist customers perceive how their our bodies reply to particular meals and train patterns and make the fitting behavioral adjustments to handle and keep their weight in the long run.
Signos didn’t share what number of sufferers are at the moment utilizing its glucose monitoring system, however Fouladgar-Mercer mentioned tens of hundreds of individuals have already tried it over time. He mentioned Signos has scaled up its CGM stock and software program capability to “deal with a fairly huge scale” following the approval.
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our publication, and be a part of our rising group at nextbusiness24.com
